MADISON, Wis.–Roche NimbleGen (SWX:RO) (SWX:ROG) (Pink Sheets: RHHBY) announced today that Beijing-based genomic services provider CapitalBio has officially joined the Roche NimbleGen Certified Service Provider (CSP) Program. CapitalBio has been certified to process customer samples for NimbleGen Gene Expression, Comparative Genomic Hybridization/Copy Number Variation (CGH/CNV), and DNA Methylation services in their lab in Beijing, China and is the first NimbleGen CSP in Asia to implement the MS 200 Microarray Scanner into their array workflow for high-resolution scanning CapitalBio brings six years experience of premier genetic research services to the Chinese scientific community, which was instrumental in their certification as a service provider.

“We will now be able to expand our service to customers through access of the complete NimbleGen Single-Color (Gene Expression) or Dual-Color (CGH/CNV & DNA Methylation) workflow. We are pleased to have passed the rigorous certification procedures and experimental standards to become part of the Roche NimbleGen CSP Program”

“The launch of the Roche NimbleGen CSP Program at CapitalBio represents a major step forward in our efforts to bring advanced DNA analysis to China” said Junquan XU, Vice President of Operations at CapitalBio. “We will now be able to expand our service to customers through access of the complete NimbleGen Single-Color (Gene Expression) or Dual-Color (CGH/CNV & DNA Methylation) workflow. We are pleased to have passed the rigorous certification procedures and experimental standards to become part of the Roche NimbleGen CSP Program”.

“Roche NimbleGen is extremely excited to welcome CapitalBio Corporation as our first certified service provider in Asia for the Gene Expression, CGH/CNV, and DNA Methylation array applications. CapitalBio Corporation’s reputation of excellence within the Chinese genomics community coupled with their adoption of the NimbleGen products effectively positions us for tremendous future growth in this rapidly developing market” said Andreas Görtz, Vice President of Marketing for Roche NimbleGen, Inc.

For more information about Roche NimbleGen, please visit www.nimblegen.com

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80’000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

About CapitalBio

CapitalBio Corporation is located in Beijing and is China’s leading developer and marketer of diagnostic biochips, microarray related instruments and microarray services. The company, founded in 2000, currently has nearly 400 employees and is closely linked to the National Engineering Research Centre for Beijing Biochip Technology. CapitalBio Corporation has broad service expertise spanning DNA and genomics analysis services, protein and transcription factor assay services, in addition to CRO services. These services have been used in studies on basic medical research and related studies, life science research and public health research. The facility and service laboratories are ISO 13485 and ISO 9001 certified and comprise a regulated quality environment. The service laboratories are also CNAS L2451 certified by the China National Accreditation Service for Conformity Assessment (CNAS). Visit www.capitalbio.com for more information.

For life science research only. Not for use in diagnostic procedures.

NIMBLEGEN is a trademark of Roche.

All trademarks used or mentioned in this release are protected by law.